(0.24%) 5 144.00 points
(0.19%) 38 514 points
(0.35%) 17 909 points
(-0.39%) $83.52
(1.98%) $1.961
(0.04%) $2 348.20
(0.47%) $27.67
(1.06%) $931.85
(-0.21%) $0.933
(-0.35%) $10.99
(-0.35%) $0.798
(1.16%) $92.94
Live Chart Being Loaded With Signals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders...
Stats | |
---|---|
今日成交量 | 5 194.00 |
平均成交量 | 24 571.00 |
市值 | 3.63M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.240 |
ATR14 | $0.0710 (2.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-29 | Singh Vanila | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Shah Vinay | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Jambulingam Thani | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Mathias Sheila | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Dubin Michael F | Buy | 25 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
75.05 |
Last 71 transactions |
Buy: 2 396 200 | Sell: 387 701 |
Virpax Pharmaceuticals, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-12.97 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-12.97 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-18.32 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Virpax Pharmaceuticals,
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。